Citations

Clear

1031 citation(s) found for "Clark, AS".

National trends in prescription drug expenditures and projections for 2023
Tichy, Eric M. , Hoffman, James M. , Tadrous, Mina , Rim, Matthew H, Suda, Katie J. , Cuéllar, Sandra , Clark, John Spencer , Newell, Mary Kate, Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 24, 2023 | Volume: 80 | Issue: 14 | Pages: 899-913

10.1093/ajhp/zxad086 | PMID 37094296 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2023 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2023 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, diabetes medications, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2023 were based on a combination of quantitative analyses and expert opinion. Results In 2022, overall pharmaceutical expenditures in the US grew 9.4% compared to 2021, for a total of $633.5 billion. Utilization (a 5.9% increase), price (a 1.7% increase) and new drugs (a 1.8% increase) drove this increase. Adalimumab was the top-selling drug in 2022, followed by semaglutide and apixaban. Drug expenditures were $37.2 billion (a 5.9% decrease) and $116.9 billion (a 10.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, new products and increased utilization growth drove growth, with a small impact from price changes. In nonfederal hospitals, a drop in utilization led to a decrease in expenditures, with price changes and new drugs contributing to growth in spending. Several new drugs that will influence spending have been or are expected to be approved in 2023. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2023, we expect overall prescription drug spending to rise by 6.0% to 8.0%, whereas in clinics and hospitals we anticipate increases of 8.0% to 10.0% and 1.0% to 3.0%, respectively, compared to 2022. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Escaping the Long Shadow Cast by Agranulocytosis
León, José de , Arrojo, Manuel , Verdoux, Hélène , Ruan, Can‐Jun , Schoretsanitis, Georgios , Rohde, Christopher , Cohen, Dan , Schulte, Peter F.J. , Kim, Se Hyun , Cotes, Robert O. , Leung, Jonathan G. , Otsuka, Yuji , Кирилочев, О.О. , Every‐Palmer, Susanna , Clark, Scott R. , Motuca, Mariano , Wilkowska, Alina , Yağcıoğlu, A. Elif Anıl , Lazáry, Judit , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Arrojo-Romero, Manuel , Kirilochev, Oleg O , Baptista, Trino , Grover, Sandeep , Every-Palmer, Susanna , Clark, Scott , McGrane, Ian , Motuca, Mariano , Olmos, Ismael , Wilkowska, Alina , Sagud, Marina , Ignjatovic Ristic, Dragana , Lazary, Judit , Sanz, Emilio J , Leung, Jonathan G , Ruan, Can-Jun , Kim, Se Hyun , Rohde, Christopher , De Las Cuevas, Carlos , Schulte, Peter F J , Anıl Yağcıoğlu, A Elif , Cotes, Robert O , Otsuka, Yuji , Schoretsanitis, Georgios , McGrane, Ian R. , Ristić, Dragana Ignjatović

Mayo Clinic

Journal of Clinical Psychopharmacology | April 17, 2023 | Volume: 43 | Issue: 3 | Pages: 239-245

10.1097/jcp.0000000000001678 | PMID 37068034 Get It

Abstract Purpose/Background A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.
Seizure occurrence is linked to multiday cycles in diverse physiological signals
Gregg, Nicholas M. , Attia, Tal Pal , Nasseri, Mona , Karoly, Philippa J. , Cui, Jie , Stirling, Rachel E. , Viana, Pedro F. , Nurse, Ewan S. , Cook, Mark , Richardson, Mark P. , Brinkmann, Benjamin H. , Pal Attia, Tal , Joseph, Boney , Karoly, Phillipa J , Cui, Jie , Stirling, Rachel E , Viana, Pedro F , Richner, Thomas J, Nurse, Ewan , Schulze-Bonhage, Andreas , Cook, Mark J , Worrell, Gregory A , Richardson, Mark P , Freestone, Dean R , Brinkmann, Benjamin H , Gregg, Nicholas M , Joseph, Boney , Richner, Thomas J. , Schulze‐Bonhage, Andreas , Worrell, Gregory A. , Freestone, Dean R.

Mayo Clinic

Epilepsia | April 15, 2023 | Volume: 64 | Issue: 6 | Pages: 1627-1639

10.1111/epi.17607 | PMID 37060170 Get It

Abstract Objective The factors that influence seizure timing are poorly understood, and seizure unpredictability remains a major cause of disability. Work in chronobiology has shown that cyclical physiological phenomena are ubiquitous, with daily and multiday cycles evident in immune, endocrine, metabolic, neurological, and cardiovascular function. Additionally, work with chronic brain recordings has identified that seizure risk is linked to daily and multiday cycles in brain activity. Here, we provide the first characterization of the relationships between the cyclical modulation of a diverse set of physiological signals, brain activity, and seizure timing. Methods In this cohort study, 14 subjects underwent chronic ambulatory monitoring with a multimodal wrist‐worn sensor (recording heart rate, accelerometry, electrodermal activity, and temperature) and an implanted responsive neurostimulation system (recording interictal epileptiform abnormalities and electrographic seizures). Wavelet and filter–Hilbert spectral analyses characterized circadian and multiday cycles in brain and wearable recordings. Circular statistics assessed electrographic seizure timing and cycles in physiology. Results Ten subjects met inclusion criteria. The mean recording duration was 232 days. Seven subjects had reliable electroencephalographic seizure detections (mean = 76 seizures). Multiday cycles were present in all wearable device signals across all subjects. Seizure timing was phase locked to multiday cycles in five (temperature), four (heart rate, phasic electrodermal activity), and three (accelerometry, heart rate variability, tonic electrodermal activity) subjects. Notably, after regression of behavioral covariates from heart rate, six of seven subjects had seizure phase locking to the residual heart rate signal. Significance Seizure timing is associated with daily and multiday cycles in multiple physiological processes. Chronic multimodal wearable device recordings can situate rare paroxysmal events, like seizures, within a broader chronobiology context of the individual. Wearable devices may advance the understanding of factors that influence seizure risk and enable personalized time‐varying approaches to epilepsy care.
Use of the Revised Second Victim Experience and Support Tool to Examine Second Victim Experiences of Respiratory Therapists
Allender, Erica A, Bottema, Sophia M, Bosley, Christopher, Holst, Stephanie J, Clark, William J., Weaver, Amy L. , Finney, Robyn E. , Bosley, Christopher L., Rivera-Chiauzzi, Enid Y , Clark, William J, Rivera‐Chiauzzi, Enid Y. , Holst, Stephanie J.

Mayo Clinic

Respiratory Care | April 11, 2023 | Volume: 68 | Issue: 6 | Pages: 749-759

10.4187/respcare.10719 | PMID 37041030 Get It

BACKGROUND: Respiratory therapists (RTs) work alongside allied health staff, nurses, and physicians during stressful and traumatic events that can be associated with emotional and physiological implications known as second victim (SV) experiences (SVEs). This study aimed to evaluate SVEs of RTs, including both positive and negative implications. METHODS: RTs within a large academic health care organization across Minnesota, Wisconsin, Florida, and Arizona were asked to participate in an anonymous survey that included the validated Second Victim Experience and Support Tool-Revised to assess SVEs as well as desired support services. RESULTS: Of the RTs invited to participate, 30.8% (171/555) completed the survey. Of the 171 survey respondents, 91.2% (156) reported that they had been part of a stressful or traumatic work-related event as an RT, student, or department support staff member. Emotional or physiologic implications experienced by respondents as SVs included anxiety 39.1% (61/156), reliving of the event 36.5% (57/156), sleeplessness 32.1% (50/156), and guilt 28.2% (44/156). Following a stressful clinical event, 14.8% (22/149) experienced psychological distress, 14.2% (21/148) experienced physical distress, 17.7% (26/147) indicated lack of institutional support, and 15.6% (23/147) indicated turnover intentions. Enhanced resilience and growth were reported by 9.5% (14/147). Clinical and non-clinical events were reported as possible triggers for SVEs. Nearly half of respondents 49.4% (77/156) indicated feeling like an SV due to events related to COVID-19. Peer support was the highest ranked form of desired support following an SVE by 57.7% (90/156). CONCLUSIONS: RTs are involved in stressful or traumatic clinical events, resulting in psychological/physical distress and turnover intentions. The COVID-19 pandemic has had a significant impact on RTs’ SVEs, highlighting the importance of addressing the SV phenomenon among this population.
Mitochondrial Base Editing: Recent Advances towards Therapeutic Opportunities
Kar, Bibekananda , Restrepo-Castillo, Santiago , Sabharwal, Ankit , Ekker, Stephen C. , Castillo, Santiago R , Ekker, Stephen C , Sabharwal, Ankit , Kar, Bibekananda , Clark, Karl J.

Mayo Clinic

International Journal of Molecular Sciences | March 20, 2023 | Volume: 24 | Issue: 6 | Pages: 5798

10.3390/ijms24065798 | PMID 36982871 Get It

Mitochondria are critical organelles that form networks within our cells, generate energy dynamically, contribute to diverse cell and organ function, and produce a variety of critical signaling molecules, such as cortisol. This intracellular microbiome can differ between cells, tissues, and organs. Mitochondria can change with disease, age, and in response to the environment. Single nucleotide variants in the circular genomes of human mitochondrial DNA are associated with many different life-threatening diseases. Mitochondrial DNA base editing tools have established novel disease models and represent a new possibility toward personalized gene therapies for the treatment of mtDNA-based disorders.
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
Haddad, Tufia C. , D’Assoro, Antonino B. , Carter, Jodi M. , McMenomy, Brendan P., Santo, Katelyn, Karuturi, Meghan , Morikawa, Aki , Marcom, P. Kelly, Oh, Sun Young , Clark, Amy S. , Keyomarsi, Khandan , Hobday, Timothy J. , Peethambaram, Prema P. , O’Sullivan, Ciara C. , Leon‐Ferre, Roberto A. , Liu, Minetta C. , D'Assoro, Antonino B, O'Sullivan, Ciara C, Ingle, James N. , Carter, Jodi , Suman, Vera J. , Giridhar, Karthik V. , Mayer, Erica L. , Marcom, P. Kelly, Isaacs, Claudine , Mayer, Ingrid A. , Goetz, Matthew P.

Mayo Clinic

JAMA Oncology | March 9, 2023 | Volume: 9 | Issue: 6 | Pages: 815

10.1001/jamaoncol.2022.7949 | PMID 36892847 Get It

ImportanceAurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i–resistant MBC is unknown.ObjectiveTo assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC.Design, Setting, and ParticipantsThis phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)–negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (<10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022.InterventionsAlisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2).Main Outcomes and MeasuresImprovement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%.ResultsAll 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]).Conclusions and RelevanceThis randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i–resistant MBC. The overall safety profile was tolerable.Trial RegistrationClinicalTrials.gov Identifier: NCT02860000
Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study
Mahmoud, Sherif Hanafy , Hefny, Fatma , Panos, Nicholas , Delucilla, Laura, Ngan, Zinquon, Perreault, Marc M. , Hamilton, Leslie A. , Rowe, A. Shaun , Buschur, Pamela , Owusu‐Guha, Jocelyn , Almohaish, Sulaiman , Sandler, Melissa , Armahizer, Michael , Barthol, Colleen , Hintze, Trager D , Cantin, Anna, Traeger, Jessica, Blunck, Joseph R. , Shewmaker, Justin , Burgess, Sarah , Kaupp, Kristin , Brown, Caitlin S. , Clark, Sarah L. , Wieruszewski, Erin D. , Tesoro, Eljim P. , Ammar, Abdalla , Binning, Mandy J., Naydin, Stanislav, Fox, Neal S., Peters, David M. , Mahmoud, Leana , Keegan, Shaun, Hefny, Fatma R , Cook, Aaron M , Blunck, Joseph R , Brown, Caitlin S , Ammar, Mahmoud A , Peters, David M , Brophy, Gretchen M , Barra, Megan E. , Cook, Aaron M. , Brophy, Gretchen M.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | March 7, 2023 | Volume: 43 | Issue: 4 | Pages: 279-290

10.1002/phar.2791 | PMID 36880540 Get It

AbstractBackgroundNimodipine improves outcomes following aneurysmal subarachnoid hemorrhage (aSAH) and current guidelines suggest that patients with aSAH receive nimodipine for 21 days. Patients with no difficulty swallowing will swallow the whole capsules or tablets; otherwise, nimodipine liquid must be drawn from capsules, tablets need to be crushed, or the commercially available liquid product be used to facilitate administration through an enteral feeding tube (FT). It is not clear whether these techniques are equivalent. The goal of the study was to determine if different nimodipine formulations and administration techniques were associated with the safety and effectiveness of nimodipine in aSAH.MethodsThis was a retrospective multicenter observational cohort study conducted in 21 hospitals across North America. Patients admitted with aSAH and received nimodipine by FT for ≥3 days were included. Patient demographics, disease severity, nimodipine administration, and study outcomes were collected. Safety end points included the prevalence of diarrhea and nimodipine dose reduction or discontinuation secondary to blood pressure reduction. Predictors of the study outcomes were analyzed using regression modeling.ResultsA total of 727 patients were included. Administration of nimodipine liquid product was independently associated with higher prevalence of diarrhea compared to other administration techniques/formulations (Odds ratio [OR] 2.28, 95% confidence interval [CI] 1.41–3.67, p‐value = 0.001, OR 2.76, 95% CI 1.37–5.55, p‐value = 0.005, for old and new commercially available formulations, respectively). Bedside withdrawal of liquid from nimodipine capsules prior to administration was significantly associated with higher prevalence of nimodipine dose reduction or discontinuation secondary to hypotension (OR 2.82, 95% CI 1.57–5.06, p‐value = 0.001). Tablet crushing and bedside withdrawal of liquid from capsules prior to administration were associated with increased odds of delayed cerebral ischemia (OR 6.66, 95% CI 3.48–12.74, p‐value <0.0001 and OR 3.92, 95% CI 2.05–7.52, p‐value <0.0001, respectively).ConclusionsOur findings suggest that enteral nimodipine formulations and administration techniques might not be equivalent. This could be attributed to excipient differences, inconsistency and inaccuracy in medication administration, and altered nimodipine bioavailability. Further studies are needed.
The effects of COVID‐19 on pediatric and adult solid organ transplant recipients and the emergence of telehealth
Shah, Raghav , Marks, Stephen D. , Johnson, Jonathan N. , Nied, Matthew, Bhatt, Girish Chandra , Bonham, Clark A. , Datla, Nithin, Sethi, Sidharth Kumar , Shah, Raghav , Johnson, Jonathan , Sethi, Sidharth Kumar , Raina, Rupesh , Bartosh, Sharon

Mayo Clinic

Pediatric Transplantation | March 7, 2023 | Volume: 27 | Issue: 4 | Pages: No page available

10.1111/petr.14490 | PMID 36879358 Get It

AbstractBackgroundThe SARS‐CoV‐2 pandemic and corresponding acute respiratory syndrome have affected all populations and led to millions of deaths worldwide. The pandemic disproportionately affected immunocompromised and immunosuppressed adult patients who had received solid organ transplants (SOTs). With the onset of the pandemic, transplant societies across the world recommended reducing SOT activities to avoid exposing immunosuppressed recipients. Due to the risk of COVID‐19‐related outcomes, SOT providers adapted the way they deliver care to their patients, leading to a reliance on telehealth. Telehealth has helped organ transplant programs continue treatment regimens while protecting patients and physicians from COVID‐19 transmission. This review highlights the adverse effects of COVID‐19 on transplant activities and summarizes the increased role of telehealth in the management of solid organ transplant recipients (SOTRs) in both pediatric and adult populations.MethodsA comprehensive systematic review and meta‐analysis were conducted to accentuate the outcomes of COVID‐19 and analyze the efficacy of telehealth on transplant activities. This in‐depth examination summarizes extensive data on the clinical detriments of COVID‐19 in transplant recipients, advantages, disadvantages, patient/physician perspectives, and effectiveness in transplant treatment plans via telehealth.ResultsCOVID‐19 has caused an increase in mortality, morbidity, hospitalization, and ICU admission in SOTRs. Telehealth efficacy and benefits to both patients and physicians have increasingly been reported.ConclusionsDeveloping effective systems of telehealth delivery has become a top priority for healthcare providers during the COVID‐19 pandemic. Further research is necessary to validate the effectiveness of telehealth in other settings.
Clinicopathological associations of hemispheric dominance in primary progressive apraxia of speech
Robinson, Carling G. , Utianski, Rene L. , Singh, Neha Atulkumar , Pham, Nha Trang Thu, Ertekin‐Taner, Nilüfer , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Clark, Heather A, Utianski, Rene L , Singh, Neha Atulkumar , Whitwell, Jennifer , Josephs, Keith A , Duffy, Joseph R. , Clark, Heather A., Machulda, Mary M. , Botha, Hugo , Dickson, Dennis W.

Mayo Clinic

European Journal of Neurology | March 4, 2023 | Volume: 30 | Issue: 5 | Pages: 1209-1219

10.1111/ene.15764 | PMID 36869612 Get It

AbstractObjectivePrimary progressive apraxia of speech (PPAOS) is associated with imaging abnormalities in the lateral premotor cortex (LPC) and supplementary motor area (SMA). It is not known whether greater involvement of these regions in either hemisphere is associated with demographics, presenting, and/or longitudinal features.MethodsIn 51 prospectively recruited PPAOS patients who completed [18F]‐fluorodeoxyglucose (FDG) positron emission tomography (PET), we classified patients as left‐dominant, right‐dominant, or symmetric, based on visual assessment of the LPC and SMA on FDG‐PET. SPM and statistical analyses of regional metabolic values were performed. Diagnosis of PPAOS was made if apraxia of speech was present and aphasia absent. Thirteen patients completed ioflupane‐123I (dopamine transporter [DAT]) scans. We compared cross‐sectional and longitudinal clinicopathological, genetic, and neuroimaging characteristics across the three groups, with area under the receiver‐operating curve (AUROC) determined as a measure of effect size.ResultsIn all, 49% of the PPAOS patients were classified as left‐dominant, 31% as right‐dominant, and 20% as symmetric, which was supported by results from the SPM and regional analyses. There were no differences in baseline characteristics. Longitudinally, right‐dominant PPAOS showed faster rates of progression of ideomotor apraxia (AUROC 0.79), behavioral disturbances (AUROC 0.84), including disinhibition symptoms (AUROC 0.82) and negative behaviors (AUROC 0.82), and parkinsonism (AUROC 0.75) compared to left‐dominant PPAOS. Symmetric PPAOS showed faster rates of dysarthria progression compared to left‐dominant (AUROC 0.89) and right‐dominant PPAOS (AUROC 0.79). Five patients showed abnormal DAT uptake. Braak neurofibrillary tangle stage differed across groups (p = 0.01).ConclusionsPatients with PPAOS and a right‐dominant pattern of hypometabolism on FDG‐PET have the fastest rates of decline of behavioral and motor features.
Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Stringer-Reasor, Erica , Chien, Jo, Albain, Kathy S. , Nanda, Rita , Clark, Amy S. , Lu, Janice, Asare, Smita , Lu, Ruixiao , Pitsouni, Maria, Wilson, Amy , Perlmutter, Jane , Rugo, Hope, Schwab, Richard B. , Veer, Laura van ‘t , Berry, Donald A. , Investigators, I-SPY, Shatsky, Rebecca , Wallace, Anne M. , Boughey, Judy C. , Han, Hyo S , Isaacs, Claudine , Kalinsky, Kevin M. , Mitri, Zahi Ibrahim , Vaklavas, Christos , Thomas, Alexandra , Trivedi, Meghna S. , Symmans, W. Fraser , Hylton, Nola M. , Veer, Laura J. van’t , Yee, Douglas , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: PD11-01-PD11-01

10.1158/1538-7445.sabcs22-pd11-01 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status to evaluate novel agents as neoadjuvant therapy for high-risk breast cancer. The primary endpoint is pathologic complete response (pCR). Cemiplimab (Cemi) is a PD-1 inhibitor approved for the treatment of NSCLC, cutaneous basal, and squamous cell cancer. Here, we report current efficacy rates of Cemi in combination with paclitaxel followed by AC. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment; HR positive (HR+) patients had to be MP high risk. Treatment included paclitaxel 80 mg/m2 IV weekly x 12 and Cemi 350 mg IV given q3weeks x 4, followed by doxorubicin/cyclophosphamide (AC) every 2 weeks x 4. The control arm was weekly paclitaxel x 12 followed by AC every 2-3 weeks x 4. All patients undergo serial MRI imaging; and imaging response (at 3 weeks, 12 weeks and prior to surgery) were used along with accumulating pCR data to continuously update and estimate pCR rates for trial arms. Analysis was modified intent to treat. Patients who switched to non-protocol therapy count as non-pCR. The goal is to identify (graduate) regimens with ≥85% Bayesian predictive probability of success (i.e. demonstrating superiority to control) in a future 300-patient phase 3 neoadjuvant trial with a pCR endpoint within responsive signatures. Cemi was eligible to graduate in 3 pre-defined signatures: HER2-, HR-HER2-, and HR+HER2-. To adapt to changing standard of care, we constructed “dynamic controls” comprising ‘best’ alternative therapies using I-SPY 2 and external data and estimated the probability of Cemi being superior to the dynamic control. Results: 60 HER2- patients (28 HR+ and 32 HR-) received Cemi arm treatment. The control group included 357 patients with HER2- tumors (201 HR+ and 156 HR-) enrolled since March 2010. Cemi graduated in HR-/HER2- signature. Estimated pCR rates (as of June 2022) are summarized in the table. Immune-related endocrine disorders include: hypothyroid (14.5%), adrenal insufficiency (10%), hyperthyroid (4.8%),) and thyroiditis (3.2%). Only one grade 3 adrenal insufficiency was observed. All immune related AE’s were manageable. Additional biomarker analyses are ongoing and will be presented at the meeting. Response predictive subtypes (Immune+ vs Immune-) and additional predictive biomarkers were assessed. Associations with pCR will be presented at SABCS. Conclusion: The I-SPY 2 study aims to assess the probability that investigational regimens will be successful in a phase 3 neoadjuvant trial. Anti-PD-1 therapy with Cemi resulted in a higher predicted pCR rate in HR-/HER2- 55 rate% disease compared to control at 29%. Immune-mediated AE’s were observed. This data is consistent with previously published data using check point inhibitors in early-stage HR-/HER2- breast cancer. Estimated pCR rates Citation Format: Erica Stringer-Reasor, Rebecca A. Shatsky, Jo Chien, Anne Wallace, Judy C. Boughey, Kathy S. Albain, Hyo S. Han, Rita Nanda, Claudine Isaacs, Kevin Kalinsky, Zahi Mitri, Amy S. Clark, Christos Vaklavas, Alexandra Thomas, Meghna S. Trivedi, Janice Lu, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van ’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators. PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD11-01.